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RESUMO
Proteção Cerebral em Pacientes Idosos  
durante Implante de Stent Carotídeo
Introdução: O tipo de proteção cerebral utilizado durante o 
implante de stent carotídeo é controverso em idosos. Nosso 
objetivo foi avaliar os resultados dos dispositivos de proteção 
embólica cerebral (PEC), proximal e distal, em pacientes 
> 70 anos de idade, por meio da ressonância magnética 
ponderada de difusão (RM-PD). Métodos: Entre 2008 e 
2011, 60 pacientes com indicação de stent carotídeo foram 
randomizados para PEC com Mo.Ma® ou Angioguard®, dos 
quais 26 tinham > 70 anos de idade. Os resultados da RM-
PD realizada antes e 48 horas após o procedimento foram 
avaliados por neurologista independente e cego para o tipo 
de PEC utilizado. Foram analisados o número de novos focos 
isquêmicos, sua localização e o tamanho. Resultados: Novos 
focos isquêmicos cerebrais foram encontrados em 8/12 (66,7%) 
pacientes do grupo Mo.Ma® e em 12/14 (85,7%) pacientes 
do grupo Angioguard® (P = 0,37). A maioria das lesões (> 
90%) era ipsilateral à artéria tratada em ambos os grupos, e 
o tamanho das lesões foi < 0,5 cm na maioria dos casos. O 
número de lesões por paciente foi menor com o dispositivo 
Mo.Ma® (mediana [variação]: 3 [1 a 8] lesões vs. 15 [2 a 76] 
lesões; P < 0,001). Todos os pacientes que tiveram mais de 40 
lesões pertenciam ao grupo Angioguard®. Conclusões: Mesmo 
utilizando PEC (proximal ou distal), novas lesões isquêmicas 
foram observadas em ambos os grupos em pacientes idosos. 
Proporcionalmente maior número de pacientes com Angioguard® 
teve novos focos isquêmicos se comparados aos pacientes do 
grupo Mo.Ma®. O dispositivo de PEC Mo.Ma® parece diminuir 
o número de lesões por paciente.
DESCRITORES: Idoso. Estenose das carótidas. Ressonância 
magnética ponderada por difusão. Angioplastia. Stents. An-
giografia cerebral.
ABSTRACT
Background: The type of cerebral protection used during 
carotid stenting in the elderly is controversial. Our objective 
was to evaluate the results of proximal and distal cerebral 
embolic protection devices (EPDs), in patients > 70 years 
through diffusion-weighted magnetic resonance imaging 
(DW-MRI). Methods: Between 2008 and 2011, 60 patients 
with indication for carotid stenting were randomized to EPD 
with Mo.Ma® or Angioguard®, of which 26 patients were > 
70 years of age. Results of DW-MRI performed before and 48 
hours after the procedure were evaluated by an independent 
neurologist blinded to the type of EPD used. New ischemic 
lesions, their localization and size were analyzed. Results: 
New cerebral ischemic lesions were found in 8/12 (66.7%) 
patients in the Mo.Ma® group and 12/14 (85.7%) patients in 
the Angioguard® group (P = 0.37). The vast majority of the 
lesions (> 90%) were ipsilateral to the treated artery in both 
groups and the size of the lesions was < 0.5 cm in most 
cases. The number of lesions per patient was lower with the 
Mo.Ma® device (median [variation]: 3 [1 to 8] lesions vs 15 
[2 to 76] lesions; P < 0.001). All of the patients with more 
than 40 lesions were in the Angioguard® group. Conclusions: 
Despite the use of EPDs (proximal or distal), new ischemic 
lesions were observed in both groups in elderly patients. A 
proportionately larger number of patients with Angioguard® 
had new ischemic lesions when compared to those with 
Mo.Ma®. The Mo.Ma® device seems to decrease the number 





DESCRIPTORS: Aged. Carotid stenosis. Diffusion-weighted 
magnetic ressonance imaging. Angioplasty. Stents. Cerebral 
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E xtracranial carotid disease has surgical endarterec-tomy as the standard treatment. The percutaneous treatment with stent implantation1 has emerged as 
a less invasive alternative for high-surgical risk patients.
The microemboli generated during the percutaneous 
procedure are the biggest challenge to be overcome. 
Theron et al.2 were the first to report the use of ce-
rebral embolic protection devices (EPDs) in clinical 
practice. They used a balloon occlusion system in the 
internal carotid, distal to the lesion; at the end of the 
procedure, when analysing the aspirated material, they 
found particles with potential risk of embolisation of 
intracranial vessels.
Currently, there are two strategies for cerebral embolic 
protection: proximal EPDs, which produce endovascular 
clamping of blood flow through expanded balloons in 
the common carotid artery and the external carotid artery, 
and that cause interruption or reversal of blood flow in 
the internal carotid, allowing for the capture of particles 
of all sizes through aspiration of the blood column; and 
distal EPDs, constituted by filters with pores that capture 
particles > 100 μm, positioned distally to the internal 
carotid artery lesion. The latter are simpler to use and 
are the preferred choice of interventionists.
This study aimed to analyse the behavior of two 
different types of EPDs in elderly patients (> 70 years), 
evaluating the findings of the diffusion-weighted magnetic 
resonance imaging (DW-MRI) before and 48 hours after 
carotid stent implantation.
METHODS
This was a prospective, single-center, randomized 
study that included patients with carotid stenosis, whether 
symptomatic or asymptomatic, candidates for stenting 
and capable of indistinctly receiving the proximal EPD 
Mo.Ma® (Invatec Corporation-Brescia, Italy) or distal 
EPD Angioguard® (Cordis Endovascular – Miami Lakes, 
United States) (Figure 1).
All patients received the nitinol carotid stent 
PRECISE® (Cordis Endovascular – Miami Lakes, United 
States), which is an open-cell self-expanding stent, and 
requires a 6F release system.
DW-MRI was used to detect hyperacute brain 
microinfarcts caused by microparticles released during 
the endovascular procedure, with the assessment of the 
number, size, and location of new ischemic foci. DW-
MRI images were obtained in a 3.0 Tesla equipment 
(Excite HD; GE Medical Systems – Milwaukee, USA) 
with an eight-channel head coil. The DW-MRI was 
performed before and 48 hours after the percutaneous 
procedure. The results were evaluated by an independent 
neurologist blinded to the type of EPD used. Patients 
were followed-up for a period of at least one year.
Randomisation of patients to the Mo.Ma® and 
Angioguard® groups was accomplished electronically 
using the Complex Samples module of SPSS software. 
To ensure balance in relation to the number of patients 
in each group, randomisation was performed in groups 
of six (three for the Mo.Ma® group and three for the 
Angioguard® group).
All the fundamental requirements of Resolutions 
no. 196/96, 251/97, and 292/99, on guidelines and 
regulating norms in research involving human subjects, 
by the National Health Council/National Board of 
Research Ethics/Brazilian Health Surveillance Agency 
(Agência Nacional de Vigilância Sanitária – ANVISA) 
were met, as well as the Good Practices in Clinical 
Research of ICH – GCP.
Figure 1 – Eligibility criteria.
Inclusion criteria Exclusion criteria
Patients of both genders, aged ≥ 40 years Dementia
Symptomatic and carotid lesion > 50% Extensive ipsilateral cerebral infarction
Asymptomatic and carotid lesion > 80% Cerebral infarction with hemorrhagic transformation < 60 days
Clinical indication for percutaneous coronary intervention with stenting Cerebral hemorrhagic < 1 month
Capable of using the proximal and distal carotid protection devices indistinctly Lesion located in the common carotid or intracranial artery
Occlusion of the ipsilateral internal carotid
Occlusion of the contralateral internal carotid artery
Occlusion of the ipsilateral external carotid
Significant injury to the vertebrobasilar territory
Atrial fibrillation using oral anticoagulants
Unstable angina or myocardial infarction < 30 days
Claustrophobia
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The main objective of this study was to compare, 
by DW-MRI, the incidence and extension of ischemic 
events after carotid stenting in patients > 70 years of 
age, using two types of EPD (proximal vs. distal).
The following definitions were adopted:
– Transient ischemic accident: defined as a tempo-
rary alteration in blood supply to a brain area, resulting 
in sudden and brief (less than 24 hours, typically less 
than one hour) decrease of brain functions. Symptoms 
vary depending on the affected area, and include visual 
alterations, speech alterations, and localized sensory 
and motor deficiencies.
– Stroke: new neurological deficit with focal symp-
toms and signs consistent with focal ischemic lasting 
over 24 hours. Minor stroke causes neurological deficit 
that completely resolves within 30 days. Major stroke 
causes neurological deficit that does not completely 
resolve within 30 days.
– Procedural success: when there was technical 
success (capacity to use the cerebral EPD and stent 
implantation with a residual lesion ≤ 30 %), associated 
with clinical success (no cerebrovascular and cardio-
vascular events during the procedure).
– Myocardial infarction: symptoms compatible with 
myocardial ischemic associated with ischemic electro-
cardiographic alterations and increase of at least two-
fold the normal value of myocardial necrosis markers.
Statistical Analysis
In the statistical analysis, qualitative data were sum-
marized as absolute and relative frequencies (percent-
ages) and compared with Student’s t-test. Quantitative 
data were expressed as means and standard deviations 
and compared using Fisher’s exact test. 
A value of P < 0.05 was considered significant. 
The statistical softwares used were SPSS for Windows, 
version 19.0, and R (R Core Team), version 16.0.
RESULTS
Between July of 2008 and July of 2011, 60 patients 
were randomized (Figure  2). During the trial period, 
over 250 procedures with carotid stent implantation 
were performed at the institution, and 67 patients met 
the inclusion criteria and were randomized. During 
the trial, two patients withdrew their consent and five 
others were excluded because, during the procedure, 
the anatomical characteristics of the lesions made them 
more suitable for one of the cerebral EPDs, violating 
the inclusion criteria. Of the 60 patients included, 26 
(43.3%) were aged >  70 years and were the subject 
of this analysis.
Twelve patients were allocated to the Mo.Ma® 
group and 14 to the Angioguard® group, with a mean 
age of 75 ± 3.5 years and similar clinical character-
istics (Table 1).
Successful stent implantation was attained in all 
patients with the EPD indicated at the randomisation, 
without crossover. The mean procedure time was similar 
between the groups (29.5 ± 10.3 min vs. 24.2 ± 10.4 
minutes; P = 0.21).
New cerebral ischemic foci were found in 8/12 
(66.7%) patients in Mo.Ma® group and in 12 /14 
(85.7%) patients in Angioguard® group (P = 0.37). The 
number of lesions per patient was lower with Mo.Ma® 
device (median [range]: 3 lesions [1 to 8] vs. 15 lesions 
[2-76]; P < 0.001). All five patients with > 40 lesions 
were from the Angioguard® group (Figure 3).
The lesions were mostly ipsilateral to the artery 
treated in both groups. Figure 4 shows the anatomical 
distribution of cerebral microlesions according to the 
type of cerebral protection. The lesions were mostly 
small (< 0.5 cm in over 90% of them).
Procedural success was 96.2%, with one patient 
presenting stroke during the intervention, which showed 
complete recovery in less than 30 days (minor stroke). 
A subsequent late DW-MRI performed in this patient 
showed the disappearance of lesions (Figure 5). At the 
follow-up of at least one year, no death or major stroke 
occurred in the two groups of patients.
DISCUSSION
The main findings of the present study were that 
the number of brain microlesions per patient at the 
DW-MRI was significantly lower in the group of elderly 
patients treated with Mo.Ma® when compared to the 
group treated with Angioguard®, and that the carotid 
Figure 2 – Study flow chart. IDPC, Instituto Dante Pazzanese de Car-
diologia; DW-MRI, diffusion-weighted magnetic resonance imaging.
• Duplex carotid scan (stenosis > 70%)
• Probable carotid stenting indication
• Angiography of brain and neck vessels
• Randomisation
• First DW-MRI
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stent implantation with two types of EPD is feasible in 
elderly patients and effective in terms of prevention of 
major clinical events.
The underlying causes of the lower incidence of 
cerebral microembolisation at the DW-MRI in elderly 
patients who used proximal cerebral protection are 
not fully understood, and may include a combination 
of factors. Distal EPD needs to overcome the lesion 
before the protection starts working effectively. The 
main determinants of increased risk of stroke in these 
patients are the complexity of the aortic arch (higher 
proportion of type III aortic arch),3 type of treated le-
sion,4,5 degree of calcification,6 and excessive angulation 
and tortuosity of the approached carotid.7
The study by Brott et al.8 in 2,502 patients, demon-
strated no significant difference between carotid stenting 
with distal filter EPD and endarterectomy during the 
four years of follow-up regarding the primary outcome 
of death, infarction, and stroke (7.2% vs. 6.8%; P = 
0.51). Moreover, no difference was observed regarding 
events between genders (male/female) and presence 
of symptoms (symptomatic/asymptomatic). Regarding 
age, an increasing association was observed between 








Age, years 75.4 ± 3.7 74.8 ± 3.3 0.67
Male gender, n (%) 9 (75) 5 (35.7) 0.06
Diabetes, n (%) 4 (33.3) 5 (35.7) > 0.99
Arterial hypertension, n (%) 10 (83.3) 14 (100) 0.20
Dyslipidaemia, n (%) 9 (75) 10 (71.4) > 0.99
Smoking, n (%) 1 (8.3) 2 (14.3) > 0.99
Coronary artery disease, n (%) 8 (66.7) 9 (64.3) > 0.99
Previous coronary artery bypass graft surgery, n (%) 2 (16.7) 3 (21.4) > 0.99
Renal failure, n (%) 3 (25) 3 (21.4) > 0.99
Symptoms < 6 months, n (%) 2 (16.7) 1 (7.1) 0.58
Figure 3 – Distribution of frequency of new ischemic lesions in elderly 
patients with Mo.Ma® (n = 12) and Angioguard® (n = 14) devices.
Figure 4 – Anatomical distribution of new ischemic brain lesions in 





























(n = 31 lesions)
Angioguard® group
(n = 327 lesions)
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Risk factors for use of distal EPD were studied 
in registries and reviews;9 age and diabetes were 
systematically identified, as well as gender, smoking 
status, and the afore mentioned anatomical risk fac-
tors. However, it is still unknown whether the same 
factors for distal EPD must be considered for proximal 
EDP. When analysing the studies addressing the use of 
proximal EPD, it was observed that in 2,397 patients,10 
there was a composite primary outcome of death, 
total stroke, or myocardial infarction at 30 days of 
2.5 %, with incidence of death in 0.40%, of stroke in 
1.71%, and myocardial infarction in 0.02%. The only 
independent predictors of events (death, myocardial 
infarction, and stroke) were age and diabetes. Of note, 
in all subgroups, including octogenarian patients, the 
incidence of events was < 2.6%.
Finally, with the introduction of proximal EPD, 
rates of adverse events greatly decreased, with high-risk 
patients showing the greatest benefit (elderly included). 
To date, there have been no randomized studies compar-
ing carotid stenting with proximal cerebral protection 
and endarterectomy.
Study limitations
The main limitations of this study refer to the small 
number of cases, due to the difficulty to find patients 
who could indistinctly use both EDPs, and the absence 
of angiographic characterisation of the population, 
which could unbalance the groups, despite the ran-
domization.
The small number of patients restricts the extrapo-
lation of the present conclusions, which are limited 
to the displayed scenario and the EPD devices used, 
and thus cannot be extended to other commercially 
available devices.
CONCLUSIONS
Patients > 70 years of age appear to have better 
results when undergoing carotid stenting with proximal 
EPD (Mo.Ma®), showing fewer microinfarcts when com-
pared to those using distal EPD (Angioguard®). Further 
studies with clinical outcomes are recommended to 
confirm the present findings.
Figure 5 – In A, pre-intervention: on the left, angiography showing a 90% lesion in the left carotid; on the right, diffusion imaging showing old 
white matter infarct in the occipital lobe (arrow). In B, post-intervention: on the left, angiography showing final result after stenting; on the right, 
diffusion imaging showing hyperacute ipsilateral microinfarcts (arrows). In C, late follow-up (one year): on the left, diffusion image showing resolu-
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